Review Article

Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed?

Vikas Satyananda,1 Rohan Gupta,2 Danielle M. Hari,1 James Yeh1,2, and Kathryn T. Chen1

1Division of Surgical Oncology, Department of Surgery, Harbor-UCLA Medical Center, USA
2Division of Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, USA

Correspondence should be addressed to Kathryn T. Chen; kathryn.chen@gmail.com

Received 30 September 2018; Accepted 8 January 2019; Published 4 February 2019

Academic Editor: Niccola Funel

Copyright © 2019 Vikas Satyananda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

While significant advances have been made in the treatment of many different solid tumors, pancreatic cancer remains a glaring exception. Overall 5-year survival rates for pancreatic cancer remain in the single digits. While newer chemotherapy regimens such as FOLFIRINOX and nab-paclitaxel/gemcitabine have demonstrated modest improvement in survival benefit for metastatic disease and have improved the resectability rates of previously borderline or locally advanced tumors, clinically significant improvements from immunotherapy and targeted therapy remain to be demonstrated. Regardless, a wealth of basic science research in pancreatic cancer has been directed at understanding its aggressive biology and its resistance to therapy. We present a brief summary of key areas of laboratory research and its translation to clinical care.

1. Introduction

In the past two decades, there have been significant advances in the treatment of different cancer types, particularly with the exploding field of targeted therapy and immunotherapy. From the success story of imatinib in chronic myelogenous leukemia to programmed cell death protein (PD-1) inhibition in melanoma to chimeric antigen receptor T cell (CAR-T) therapy in refractory lymphoma, patients who were refractory to conventional cytotoxic agents now have treatment options that are effective and durable. On the other hand, advances in the treatment of pancreatic cancer have been frustratingly slow. Pancreatic cancer is notoriously aggressive and rarely curable, and these factors in turn curb research efforts. Pancreatic tumors are immune-quiescent, and single-agent immunotherapies have failed to show a significant clinical response [1–4]. This is due in part to a tumor microenvironment, characterized by a dense desmoplastic stroma, which demonstrates high inflammatory cell expression and limits intratumoral infiltration with effector T cells [5–8]. Notable efforts have been made to understand how we can break down this stromal barrier and stimulate immune response to pancreatic tumors.

While immunotherapy is at the forefront of translational research efforts, other key areas of interest include targeted therapies against tumor cells and the extracellular matrix, pathogenesis of pancreatic cancer, and methods of early detection. In this paper, we outline the trends in translational research in pancreatic cancer with respect to these elements.

2. Pathogenesis

The development of pancreatic cancer is thought to be multifactorial, with several recognized risk factors, including smoking, alcohol, diabetes, pancreatitis, and, most significantly, family history [8–10]. While hereditary gene mutations may contribute up to 10% of pancreatic cancers, the majority of gene alterations are somatic. Multiple genes have been identified which affect the molecular pathogenesis of pancreatic cancer, although with some heterogeneity. The tumor suppressor genes SMAD4 and TP53 and the protooncogene KRAS are commonly mutated and lead to progression from benign pancreatic intraepithelial neoplasia to infiltrative tumor [11–13]. Unfortunately, the identification of individual genetic alterations has not been particularly useful in therapeutic targeting, and clinical applications...
remain limited [4, 14, 15]. With whole genomic sequencing, molecular subtypes of pancreatic cancer are now better defined [13, 16–18]. One study described an average of 48 somatic gene mutations in pancreatic cancer—considerably less than breast, colorectal, or lung cancers [13]. As found in other whole genome cancer studies, this is consistent with the observation that normal pancreatic cells divide infrequently and are likely subject to fewer mutagenic processes (e.g., tobacco in lung cancer) [19]. One study identified 12 core signaling pathways as genetically targeted in over two-thirds of the 24 tumors sequenced, providing a framework for the molecular pathogenesis of pancreatic cancer [13]. Other genomic analyses have identified distinct molecular subtypes within pancreatic cancer, highlighting different pathways in the evolution of these tumors [18, 20]. Known precursors to pancreatic cancer, such as pancreatic intraepithelial neoplasia (Pan-IN) and intraductal mucinous papillary neoplasm (IPMN), virtually all harbor gene mutations [21, 22]. These findings may help direct biomarker detection for diagnosis for those precursor lesions that may progress to invasive adenocarcinoma.

In terms of germline mutations, four genes have been known to cause familial pancreatic cancer: BRCA, p16/CDKN2A, STK11, and PRSSI [16]. However, new and different germline mutations, including PALB2 and ATM [23, 24], have been recently identified. These discoveries allow for the appropriate counseling of patients who are at risk for other cancers and may also provide a mechanism for screening for pancreatic cancer, although this role is not yet well defined.

3. Early Detection

About 80–85% of patients with pancreatic adenocarcinoma are diagnosed with locally advanced or metastatic disease. Only 15–20% of patients are found to have resectable disease, with radical surgical resection improving 5-year survival from 5% to 20–25% [25]. Hence, early detection of pancreatic cancer is vital. Because of the relatively low incidence of pancreatic cancer, screening of pancreatic cancer is unlikely to be feasible in the general population. Certain circumstances may benefit from screening, including patients with a familial history, genetic predisposition syndromes associated with pancreatic cancer, patients with incidentally discovered indeterminate pancreatic cysts, or surveillance following resection of an IPMN, considered to be a field defect within the organ.

An ideal method of detection would employ a serum biomarker panel, which would be relatively noninvasive and cost-effective. Traditional serum tumor markers include serum CA19-9 and CEA. CA 19-9 is the most widely used biomarker of PDAC today. However, CA 19-9 is elevated in only 65% of patients with resectable PDAC and it can also be elevated in many other conditions, both benign (pancreatitis, cirrhosis, and obstructive jaundice from benign etiologies) and malignant (colorectal, gastric, and uterine cancers) [26]. As such, CA19-9 levels are currently most useful in assessing response to chemotherapy or detecting recurrence in patients who had elevated pretreatment levels.

Advances in proteomics with liquid chromatography–tandem mass spectrometry have allowed the identification of many potential biomarkers in the plasma of patients via high-throughput quantification. Several candidate protein molecules, including C4b-binding protein alpha chain (C4BPA), help in distinguishing chronic pancreatitis from PDAC and biliary tract cancers. Insulin-like growth factor-binding protein (IGFBP) 2 and IGFBP 3 in combination with CA 19-9 were predictive of PDAC in a sample of over 200 patients [27]. Several other studies with promising biomarkers to aid in differentiating between benign and malignant lesions require validation on a larger scale.

Another innovative method of investigating potential protein-based biomarker panels includes two independent studies that performed meta-analyses of pancreatic cancer transcriptome studies to identify multigene classifiers or pancreatic cancer [28, 29]. These studies both further validated their multigene classifiers against mouse models, formalin-fixed paraffin-embedded tissue samples, and pancreatic cancer tissue microarrays. Between the two studies, there were four genes which overlapped (AHNAK2, SERPINB5, TMPRSS4, and POSTN) [28, 29], which were able to differentiate pancreatic cancer from benign pancreatic conditions, as well as provide prognostic information. Translation to real-time clinical scenarios remains to be seen.

Metabolomics involves the comprehensive study of metabolites in biological specimens. Various metabolites have been measured in conjunction with CA 19-9, including glucitol, palmitate, xylitol, inositol, histidine, sphingagine-1 phosphate, sphingomyelin d17:1, and pyruvate, and have shown increased diagnostic accuracy of PDAC detection when compared with CA 19-9 alone [30].

Noncoding RNAs (ncRNAs), both small ncRNAs (ncRNAs, <200 bases) and long ncRNAs (lncRNA, >200 bases), are also interesting biomarker candidates. ncRNAs regulate gene expression at a posttranslational level and may be representative of epigenetic alterations that drive tumorigenesis. MicroRNAs (miRNAs) are a group of sncRNAs, which have shown potential as markers for early detection of PDAC; they can be isolated from serum, plasma, pancreatic juice, stool, urine, and saliva [31]. Several studies have shown miRNA or their panels in plasma or serum have potential diagnostic value (miR-1290, miR-486-5p) with more sensitivity than CA19-9 [32, 33].

Circulating tumor cells (CTCs) have been long investigated as potential biomarkers. CTCs are cells derived from a primary cancer that have entered the vasculature and circulate within the bloodstream to seed distant organs. CTCs are currently used as a prognostic biomarker in metastatic breast, prostate, and colorectal cancers; however, they have not yet been established as a method for screening or diagnosis [34]. In pancreatic cancer, the sensitivity of CTCs in the detection of nonmetastatic pancreatic cancer ranges from 5 to 75% in studies with mostly small sample sizes and is not currently employed for diagnosis [35–37].

There are many other biomarkers that are under investigation, including circulating free DNA, cytokines, and exosomes (Table 1). In addition to its clinical utility for early
detection, these biomarkers may be important in understanding the pathogenesis of pancreatic cancer and may provide insights towards therapeutic targets.

4. Targeted Therapies

Understanding the molecular pathogenesis of pancreatic cancer allows for identification of multiple areas in cell signaling or tumor formation to target therapies, as well as to identify molecular signatures that may respond to current cytotoxic regimens. Prior attempts at targeted therapy have been largely unsuccessful, including various points of the KRAS signaling cascade. A phase II study evaluating the use of cetuximab, an antibody which binds the epidermal growth factor receptor (EGFR) expressed on tumor cells, found no improvement in survival [38], despite prior apparent antitumoral effects in mice [39, 40]. Aside from transmembrane receptor proteins, other therapies that have been unsuccessful in clinical trials include targeted agents against the Notch and JAK/STAT signaling pathways [41].

There has been some progress with targeting BRCA mutations, present in 5-10% of pancreatic cancers. Alterations in BRCA, a tumor suppressor gene, have been targeted with poly ADP ribose polymerase (PARP) inhibitors. Although several case studies reported responses to PARP inhibition in patients with BRCA mutations, a phase II study evaluating veliparib as monotherapy in patients previously treated with cytotoxic therapy showed no confirmed response [42–44]. There are ongoing trials evaluating combination therapy with chemotherapy and PARP inhibition [45, 46], which may yield more promising results. Hyaluronic acid is a hydrophilic glycosaminoglycan whose production within the tumor leads to increased interstitial tumor pressure and thus limits the access of potentially effective circulating anticancer drugs due to reduced tumor perfusion [47]. Pegvorhyaluronidase alfa (PEGPH20) targets tumor microenvironment by degrading excessive hyaluronan in the tumor microenvironment and leads to improved delivery of anticancer therapy to the tumor cells. The phase II HALO 202 randomized 279 patients with previously untreated metastatic pancreatic ductal adenocarcinoma to PEGPH20 plus nab-paclitaxel/gemcitabine or nab-paclitaxel/gemcitabine. In patients with HA-high tumors (34%), there was improvement in progression-free survival (9.2 months vs. 5.2 months) and overall survival 11.5 months vs. 8.5 months in PEGPH20 arm. There were increased muscle spasms (13% vs. 1%), neutropenia (29% vs. 18%), and myalgia (5% vs. 0%) in PEGPH20 arm [48]. The phase III trial HALO-109-301 is currently ongoing [49]. In contrast, an early phase trial of PEGPH20 with mFOLFIRINOX was closed to accrual after a futility analysis showed a hazard ratio for OS of 0.44 in favor of mFOLFIRINOX [50]. The investigators recommended not studying this drug further with FOLFIRINOX. An early phase trial evaluating the pharmacodynamics, safety, and efficacy of PEGPH20 in combination with avelumab in adult patients with chemotherapy-resistant advanced or locally advanced pancreatic ductal adenocarcinoma is ongoing [51].

Napabucasin (NAPA) is an inhibitor of cancer stemness and STAT3 pathways, which lead to cancer stem cell viability. An early phase study, presented at the 2018 ASCO meeting, showed that oral 240 mg bid NAPA in combination with nab-paclitaxel and gemcitabine was well tolerated with disease control rate which was observed in 46 out of 59 patients. There were two complete responses and 26 partial responses [52]. This combination is now being further investigated in an ongoing phase III study [53].

5. Immunotherapy

Monotherapy with T cell-directed immunotherapy via checkpoint inhibitors has been largely unsuccessful. Agents that have been clinically tested include ipilimumab and tremelimunab (anti-CTLA-4) and BMS-936559 (anti-PD-L1); these agents all failed to show benefit against pancreatic cancer in terms of overall survival [2, 3, 54]. More recently,
monotherapy with pembrolizumab (anti-PD-1) has been shown to be successful in the treatment of a range of cancers with mismatch repair (MMR) deficiency, due to high expression of mutant neoantigens that render these tumors responsive to checkpoint blockade [55, 56]. In one study, of eight patients with MMR-deficient pancreatic cancer, 25% of patients had a complete response and 37% percent had a partial response [56]. However, less than 4% of all pancreatic cancers are shown to be MMR-deficient, compared to nearly 10% for gastric cancer and 6% for colorectal cancer [56].

Sherman et al. showed that the vitamin D receptor is expressed in stroma from human pancreatic tumors. Treatment with a vitamin D agonist reduced markers of inflammation and fibrosis in pancreatitis and human tumor stroma and acted as a sensitizing agent to PD1 blockade agents in treatment of pancreatic cancer [57]. A clinical trial evaluating the role of maintenance immunotherapy and paricalcitol after best response to cytotoxic chemotherapy is ongoing [58].

Vaccine therapies are also under active investigation and have been shown to induce T cell responsiveness against tumor cells. Algenpantucel-L, created from allogenic irradiated pancreatic cancer cells to express α-GT to cause hyperacute rejection, demonstrated efficacy in animal models of melanoma and subsequently in a phase II trial in pancreatic cancer [59]. A clinical trial evaluating the role of maintenance immunotherapy and paricalcitol after best response to cytotoxic chemotherapy is ongoing [58].

Vaccine therapies are also under active investigation and have been shown to induce T cell responsiveness against tumor cells. Algenpantucel-L, created from allogenic irradiated pancreatic cancer cells to express α-GT to cause hyperacute rejection, demonstrated efficacy in animal models of melanoma and subsequently in a phase II trial in pancreatic cancer [59]. Unfortunately, a phase III trial designed to evaluate the effectiveness of algenpantucel-L in combination with a cytotoxic regimen failed to show an improvement in overall survival (press release, NewLink Genetics). GVAX-CSF, a vaccine that expresses GM-CSF and induces an immune response against the tumor, inhibited tumor growth in animal and cell models, but failed to demonstrate efficacy in a phase II trial compared to single-agent chemotherapy [60].

Strategies are being developed to unlock the potential of immunotherapy with combination therapy, particularly in MMR-proficient pancreatic cancers. Clinical trials evaluating T cell expansion with vaccine therapy followed by PD-1/PD-L1 inhibition are ongoing [61, 62]. Other trials are evaluating the efficacy of induction or combination chemotherapy to activate T cells, alongside checkpoint inhibition, as well as radiation therapy or targeted therapies alongside checkpoint inhibition (Table 2). While these combinations or strategies have shown efficacy in animal models, their benefit from clinical trials remains to be seen [63, 64]. In the interim, the search for novel immune checkpoint molecules continues.

6. Conclusion

While many advances have been made in understanding pancreatic cancer in terms of gene expression, tumor microenvironment, and molecular pathogenesis, the translation from bench to clinical management remains a challenge. Although research continues to uncover new pathways to investigate and target for therapy, very few of these targets have borne out in clinical trials thus far. A biomarker panel to reliably differentiate pancreatic precursor lesions that will progress to malignancy from those that are benign has also remained elusive. The most promising area in treating pancreatic cancer appears to be stimulating the immune response to pancreatic cancer by breaking through the tumor microenvironment and enhancing directed antitumor T cell responses with combination therapies. The results of these ongoing efforts will be revealed in the near future.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

[1] M. Aglietta, C. Barone, M. B. Sawyer et al., “A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer,” *Annals of Oncology*, vol. 25, no. 9, pp. 1750–1755, 2014.

[2] J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced..."
cancer,” *The New England Journal of Medicine*, vol. 366, no. 26, pp. 2455–2465, 2012.

[3] R. E. Royal, C. Levy, K. Turner et al., “Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma,” *Journal of Immunotherapy*, vol. 33, no. 8, pp. 828–833, 2010.

[4] L. R. Brunet, T. Hagemann, A. Gaya, S. Mudan, and A. Marabelle, “Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?,” *OncoImmunology*, vol. 5, no. 4, article e1112942, 2015.

[5] C. Feig, A. Gopinathan, A. Neesse, D. S. Chan, N. Cook, and D. A. Tuveson, “The pancreatic cancer microenvironment,” *Clinical Cancer Research*, vol. 18, no. 16, pp. 4266–4276, 2012.

[6] K. Gardian, S. Janczewska, W. L. Olszewski, and M. Durlik, “Analysis of pancreatic cancer microenvironment: role of macrophage infiltrates and growth factors expression,” *Journal of Cancer*, vol. 3, pp. 285–291, 2012.

[7] J. Kleeff, P. Beckhove, I. Esposito et al., “Pancreatic cancer microenvironment,” *International Journal of Cancer*, vol. 121, no. 4, pp. 699–705, 2007.

[8] R. H. Vonderheide and L. J. Bayne, “Inflammatory networks and immune surveillance of pancreatic carcinoma,” *Current Opinion in Immunology*, vol. 25, no. 2, pp. 200–205, 2013.

[9] P. Bansal and A. Sonnenberg, “Pancreatitis is a risk factor for pancreatic cancer,” *Gastroenterology*, vol. 109, no. 1, pp. 247–251, 1995.

[10] A. B. Lowenfels and P. Maisonneuve, “Epidemiology and risk factors for pancreatic cancer,” *Best Practice & Research Clinical Gastroenterology*, vol. 20, no. 2, pp. 197–209, 2006.

[11] T. J. Grant, K. Hua, and A. Singh, "Molecular pathogenesis of pancreatic cancer," *Progress in Molecular Biology and Translational Science*, vol. 144, pp. 241–275, 2016.

[12] A. Maitra, S. E. Kern, and R. H. Hruban, "Pancreatic organogenesis of pancreatic cancer," *Best Practice & Research Clinical Gastroenterology*, vol. 20, no. 2, pp. 211–226, 2006.

[13] S. Jones, X. Zhang, D. W. Parsons et al., "Core signaling pathways in human pancreatic cancers revealed by global genomic analyses," *Science*, vol. 321, no. 5897, pp. 1801–1806, 2008.

[14] V. Corbo, G. Tortora, and A. Scarpa, "Molecular pathology of pancreatic cancer: from bench-to-bedside translation," *Current Drug Targets*, vol. 13, no. 6, pp. 744–752, 2012.

[15] M. J. Duffey, N. C. Synnott, and J. Crown, "Mutant p53 as a target for cancer treatment," *European Journal of Cancer*, vol. 83, pp. 258–265, 2017.

[16] C. A. Iacobuzio-Donahue, V. E. Velculescu, C. L. Wolfgang, and R. H. Hruban, "Genetic basis of pancreatic cancer development and progression: insights from whole-exome and whole-genome sequencing," *Clinical Cancer Research*, vol. 18, no. 16, pp. 4257–4265, 2012.

[17] M. C. Villarroya, N. V. Rajeshkumar, I. Garrido-Laguna et al., "Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer," *Molecular Cancer Therapeutics*, vol. 10, no. 1, pp. 3–8, 2011.

[18] N. Waddell, M. Pajic, A. M. Patch et al., "Whole genomes redefine the mutational landscape of pancreatic cancer," *Nature*, vol. 518, no. 7540, pp. 495–501, 2015.

[19] L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge et al., "Signatures of mutational processes in human cancer," *Nature*, vol. 500, no. 7463, pp. 415–421, 2013.

[20] P. Bailey, D. K. Chang, K. Nones et al., "Genomic analyses identify molecular subtypes of pancreatic cancer," *Nature*, vol. 531, no. 7592, pp. 47–52, 2016.

[21] M. Kanda, H. Matthaei, J. Wu et al., "Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia," *Gastroenterology*, vol. 142, no. 4, pp. 730–733.e9, 2012.

[22] J. Wu, H. Matthaei, A. Maitra et al., "Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development," *Science Translational Medicine*, vol. 3, no. 92, article 92ra66, 2011.

[23] S. Jones, R. H. Hruban, M. K. Bhasin, K. Ndebele, O. Bucur et al., "Identification of Igf2bp2 and Igf2bp3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics," *PLoS One*, vol. 11, no. 8, article e0161009, 2016.

[24] H. Klett, H. Fuehrer, L. Zerdoun et al., "Identification and validation of a diagnostic and prognostic multi-gene biomarker panel for pancreatic ductal adenocarcinoma," *Frontiers in Genetics*, vol. 9, p. 108, 2018.

[25] M. K. Bhasin, K. Ndebele, P. Bucur et al., "Meta-analysis of transcriptome data identifies a novel 5-gene pancreaticadenocarcinoma classifier," *Oncotarget*, vol. 7, no. 17, pp. 23263–23281, 2016.

[26] T. Mayerle, H. Kalthoff, R. Reszka et al., "Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis," *Gut*, vol. 67, no. 1, pp. 128–137, 2018.

[27] S. H. Loosen, U. P. Neumann, C. Trautwein, C. Roderburg, and T. Luedde, "Current and future biomarkers for pancreatic adenocarcinoma," *Tumour Biology*, vol. 39, no. 6, 2017.

[28] Z. Cao, C. Liu, J. Xu et al., "Plasma microRNA panels to diagnose pancreatic cancer: results from a multicenter study," *Oncotarget*, vol. 7, no. 27, pp. 41575–41583, 2016.

[29] A. Li, J. Yu, H. Kim et al., "MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls," *Clinical Cancer Research*, vol. 19, no. 13, pp. 3600–3610, 2013.

[30] D. H. Moon, D. P. Lindsay, S. Hong, and A. Z. Wang, "Clinical indications for, and the future of, circulating tumor cells," *Advanced Drug Delivery Reviews*, vol. 125, pp. 143–150, 2018.

[31] F. C. Bidard, F. Huguet, C. Louvet et al., "Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP07 trial," *Annals of Oncology*, vol. 24, no. 8, pp. 2057–2061, 2013.

[32] A. de Albuquerque, I. Kubisch, G. Breier et al., "Multimarker gene analysis of circulating tumor cells in pancreatic cancer
patients: a feasibility study,” *Oncology*, vol. 82, no. 1, pp. 3–10, 2012.

[37] B. Kulemann, M. B. Pitman, A. S. Liss et al., “Circulating tumor cells found in patients with localized and advanced pancreatic cancer,” *Pancreas*, vol. 44, no. 4, pp. 547–550, 2015.

[38] P. A. Philip, J. Benedetti, C. L. Corless et al., “Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial S0205,” *Journal of Clinical Oncology*, vol. 28, no. 22, pp. 3605–3610, 2010.

[39] C. J. Bruns, C. C. Solorzano, M. T. Harbison et al., “Evidence for the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma,” *Cancer Research*, vol. 60, no. 11, pp. 2926–2935, 2000.

[40] J. P. Overholser, M. C. Prevett, A. T. Hooper, H. W. Waksal, and D. J. Hicklin, “Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice,” *Cancer*, vol. 89, no. 1, pp. 74–82, 2000.

[41] H. Hurwitz, E. van Cutsem, J. Bendell et al., “Ruxolitinib + capcicitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies,” *Investigational New Drugs*, vol. 36, no. 4, pp. 683–695, 2018.

[42] D. R. Fogelman, R. A. Wolff, S. Kopetz et al., “Evidence for the efficacy of imiparib, a PARP 1 inhibitor, in BRCA2-associated pancreatic cancer,” *Anticancer Research*, vol. 31, no. 4, pp. 1417–1420, 2011.

[43] B. Kaufman, R. Shapira-Frommer, R. K. Schnitzler et al., “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation,” *Journal of Clinical Oncology*, vol. 33, no. 3, pp. 244–250, 2015.

[44] M. A. Lowery, D. P. Kelsen, M. Capanu et al., “Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma,” *European Journal of Cancer*, vol. 89, pp. 19–26, 2018.

[45] “ABT-888 with modified FOLFFOX6 in patients with metastatic pancreatic cancer,” ClinicalTrials.gov Identifier NCT01489865, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT01489865?term=NCT01489865&rank=1.

[46] “Gemcitabine hydrochloride and cisplatin with or without veliparib or veliparib alone in treating patients with locally advanced or metastatic pancreatic cancer,” ClinicalTrials.gov Identifier NCT01585805, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT01585805?term=NCT01585805&rank=1.

[47] G. J. Doherty, M. Tempero, and P. G. Corrie, “HALO–109–301: a phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer,” *Future Oncology*, vol. 14, no. 1, pp. 13–22, 2018.

[48] S. R. Hingorani, L. Zheng, A. J. Bullock et al., “HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma,” *Journal of Clinical Oncology*, vol. 36, no. 4, pp. 359–366, 2018.

[49] “A study of PEGylated recombinant human hyaluronidase in combination with paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in participants with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma,” ClinicalTrials.gov Identifier NCT02715804, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT02715804?term=NCT02715804&rank=1.

[50] R. K. Ramanathan, S. McDonough, P. A. Philip et al., “A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139),” *Journal of Clinical Oncology*, vol. 36, Supplement 4, p. 208, 2018.

[51] “A trial of PEGPH20 in combination with avelumab in chemotherapy-resistant pancreatic cancer,” ClinicalTrials.gov Identifier NCT03481920, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT03481920?term=NCT03481920&rank=1.

[52] T. S. Bekaii-Saab, A. Starodub, B. F. El-Rayes et al., “Phase 1b/2 trial of cancer stemness inhibitor nabpapavubicin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC),” *Journal of Clinical Oncology*, vol. 36, Supplement 15, p. 4110, 2018.

[53] “A study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma,” ClinicalTrials.gov Identifier NCT02993731, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT02993731?term=NCT02993731&rank=1.

[54] E. M. O’Reilly, D. Y. Oh, N. Dhani et al., “A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study,” *Journal of Clinical Oncology*, vol. 36, Supplement 4, p. 217, 2018.

[55] D. T. Le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors with mismatch-repair deficiency,” *The New England Journal of Medicine*, vol. 372, no. 26, pp. 2509–2520, 2015.

[56] D. T. Le, J. N. Durham, K. N. Smith et al., “Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade,” *Science*, vol. 357, no. 6349, pp. 409–413, 2017.

[57] M. H. Sherman, R. T. Yu, D. D. Engle et al., “Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy,” *Cell*, vol. 159, no. 1, pp. 80–93, 2014.

[58] “A SU2C Catalyst trial of a PD1 inhibitor with or without a vitamin D analog for the maintenance of pancreatic cancer,” ClinicalTrials.gov Identifier NCT03331562, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT03331562?term=NCT03331562&rank=1.

[59] J. M. Hardacre, M. Mulcahy, W. Small et al., “Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study,” *Journal of Gastrointestinal Surgery*, vol. 17, no. 1, pp. 94–101, 2013.

[60] D. T. Le, A. H. Ko, Z. A. Wainberg et al., “Results from a phase 2b, randomized, multicenter study of GVAX pancreas and tremelimumab for pancreatic cancer: a phase 2 study,” *Journal of Clinical Oncology*, vol. 36, no. 4, pp. 2520, 2015.

[61] “Neoadjuvant/adjuvant GVAX pancreas vaccine (with CY) with or without nivolumab trial for surgically resectable pancreatic cancer,” ClinicalTrials.gov Identifier NCT02451982, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT02451982?term=NCT02451982&rank=1.
"GVAX pancreas vaccine (with CY) and CRS-207 with or without nivolumab," ClinicalTrials.gov Identifier NCT02243371, National Library of Medicine (US), Bethesda, MD, USA, https://clinicaltrials.gov/ct2/show/NCT02243371?term=NCT02243371&rank=1.

G. L. Beatty, E. G. Chiorean, M. P. Fishman et al., "CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans," Science, vol. 331, no. 6024, pp. 1612–1616, 2011.

C. Twyman-Saint Victor, A. J. Rech, A. Maity et al., "Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer," Nature, vol. 520, no. 7547, pp. 373–377, 2015.

S. Makawita, A. Dimitromanolakis, A. Soosaipillai et al., "Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9," BMC Cancer, vol. 13, no. 1, p. 404, 2013.

M. Tian, Y. Z. Cui, G. H. Song et al., "Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients," BMC Cancer, vol. 8, no. 1, p. 241, 2008.

K. Tjensvoll, M. Lapin, T. Buhl et al., "Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer," Molecular Oncology, vol. 10, no. 4, pp. 635–643, 2016.

S. A. Melo, L. B. Luecke, C. Kahlert et al., "Glypican-1 identifies cancer exosomes and detects early pancreatic cancer," Nature, vol. 523, no. 7559, pp. 177–182, 2015.